ArticleBMC cardiovascular disorders2025
Association between skeletal muscle mass and the prognosis of patients undergoing percutaneous coronary intervention: a retrospective study.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe predicted skeletal muscle mass index (pSMI) is a proven and reliable index that reflects muscle mass; however, its ability to predict major adverse cardiovascular events (MACES) in patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI) remains uncertain.
methodsA total of 1340 enrolled patients were ultimately included in the study and stratified according to the pSMI tertiles. The primary endpoint was a complex set of MACEs, including all-cause mortality, nonfatal myocardial infarction, and unplanned revascularization. The Kaplan‒Meier method was used to generate a cumulative incidence curve of MACEs and secondary endpoint events of all-cause mortality. Due to the competing risk relationship between all-cause mortality and cardiovascular mortality, non-fatal myocardial infarction, and unplanned revascularization events, a competing risk model was employed to analyze the cumulative event incidence curves of competing risk events.The restricted cubic spline analysis was conducted to examine the linear association between pSMI and the incidence of MACE. A univariate and multivariate Cox regression model was utilized to identify predictors of MACEs. The predictive value of the pSMI was evaluated by determining the area under the ROC curve.
resultsDuring a median follow-up of 31.38 months, 217 patients developed MACEs. The Kaplan-Meier survival curve showed the lowest risk of MACEs and all-cause mortality in the high pSMI group(log-rank test, P < 0.05). After adjusting for competing risk factors for all-cause death, the cumulative events of cardiac death in the T3 group were lower than other two groups (Gray's test, P < 0.001), with no significant difference in the cumulative incidence of non-fatal myocardial infarction and unplanned revascularization between the pSMI groups (Gray's test, P > 0.05). The adjusted hazard ratio (HR) for the incidence of MACEs in the highest pSMI tertile was 0.335(95% CI 0.182-0.615; P < 0.001), as shown by multivariable Cox regression analysis. Subgroup analysis revealed that the pSMI was negatively correlated with the incidence of MACEs in a population of nonelderly individuals, and those without heart failure (all P < 0.05). Both the univariate and fully adjusted restriction cubic spline (RCS) curves showed a linear relationship between the pSMI and MACEs. In addition, the inclusion of the pSMI in the basic risk prediction model improved prognostic prediction (the area under the ROC curve increased from 0.647 to 0.682, P = 0.033).
conclusionIn patients with CAD undergoing PCI, the pSMI is a protective factor and potentially simple method for assessing the risk of MACEs independently. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.